A Phase 1 interventional study of Mavacamten and Activated Charcoal with Sorbitol in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-08.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Anthrax with a site in United States — 1 open to participants now, 2 under way, none of them phase 3. Anthrax · United States.
Among the 47 studies in Anthrax with a site in United States, this one is the 29th largest by enrollment of the 40 interventional ones that give a count, is one of 2 that started in 2022, is one of 23 in phase 1, and was the 43rd registered.
75 studies on the registry are indexed under Anthrax; 12 are open to participants now.
Browse Anthrax studies →1 of the 47 studies in Anthrax with a site in United States is open now. Recruiting first, the newest first:
Rutgers, The State University of New Jersey · Sites in United States
Ages 21+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 4 Anthrax studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 10 · Phase 3 2 · Phase 4 2
First in 2002; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 100 across 57 interventional studies indexed under Anthrax.
Median enrollment 97 across the 40 interventional studies, 97 across the 7 observational. Of the 44 that completed or were terminated, 14 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 47 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 1 study filed under Anthrax — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 47 studies in Anthrax with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effects of co-administration of activated charcoal with sorbitol on the single-dose drug levels of mavacamten in healthy participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Mavacamten
Drug: Mavacamten · Drug: Activated Charcoal with Sorbitol
Drug: Mavacamten · Drug: Activated Charcoal with Sorbitol
Specified dose on specified days
Drug pages: Charcoal · Sorbitol
Specified dose on specified days
Area under the plasma concentration-time curve from time zero extrapolated to infinite time ((AUC(INF))
Time frame: Up to 2 months
Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration ((AUC(0-T))
Time frame: Up to 2 months
Maximum observed plasma concentration (Cmax)
Time frame: Up to 1 month
Number of participants with adverse events (AEs)
Time frame: Up to 3 months
Number of participants with serious adverse events (SAEs)
Time frame: Up to 3 months
Number of participants with vital sign abnormalities exceeding predefined thresholds
Time frame: Up to 3 months
Number of participants with electrocardiogram (ECG) abnormalities
Time frame: Up to 3 Months
Number of participants with physical exam abnormalities
Time frame: Up to 3 months
Number of participants with clinical laboratory evaluation abnormalities
Time frame: Up to 3 months
Time of maximum observed plasma concentration (Tmax)
Time frame: Up to 1 month
Apparent terminal plasma half-life (T-HALF)
Time frame: Up to 2 months
Concentration at 24 hours (C24)
Time frame: Up to 1 month
Ran from Apr 2022 to primary completion in Sep 2022, 4 months.
Of 11 phase 1 interventional studies under Anthrax, half reached primary completion within 14 months of starting (the median); a quarter within 8 and three quarters within 18. This study's 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MYK-461